News
- Author:
- Neil Osterweil
Publish date: June 9, 2015
Key clinical point: Adding stem cell transplantation to KRd therapy improves responses in patients with newly diagnosed multiple myeloma.
Major fi...
News
- Author:
- Neil Osterweil
Publish date: June 6, 2015
Key clinical point: Anti PD-L1 immunotherapies were effective in early clinical trials against advanced urothelial cancers.
Major finding: The ove...
News
- Author:
- Neil Osterweil
Publish date: June 4, 2015
Key clinical point: Aspirin and plasma vitamin D appear to offer survival advantages for patients with colorectal cancer.
Major finding: In a mult...
News
- Author:
- Neil Osterweil
Publish date: June 4, 2015
Key clinical point: Aspirin and plasma vitamin D appear to offer survival advantages for patients with colorectal cancer.
Major finding: In a mult...
Video
- Author:
- Neil Osterweil
Publish date: June 2, 2015
News
- Author:
- Neil Osterweil
Publish date: June 2, 2015
News
- Author:
- Neil Osterweil
Publish date: June 2, 2015
News
- Author:
- Neil Osterweil
Publish date: June 2, 2015
Key clinical point: Vonoprazan (not FDA approved) is a novel potassium-competitive acid blocker with a reported half-life longer than that of prot...
News
- Author:
- Neil Osterweil
Publish date: June 1, 2015
The NCI-MATCH trial will use genomic analysis of tumors to assign patients to the most relevant targeted therapy.
Video
- Author:
- Neil Osterweil
Publish date: June 1, 2015
News
- Author:
- Neil Osterweil
Publish date: June 1, 2015
News
- Author:
- Neil Osterweil
Publish date: May 31, 2015
Key clinical point: Elective neck dissection at the time of primary surgery for oral cancers improves overall survival.
Major finding: Elective ne...
News
- Author:
- Neil Osterweil
Publish date: May 31, 2015
Key clinical point: Eribulin is the first drug shown in a clinical trial to offer a survival advantage over existing therapies for metastatic soft...
News
- Author:
- Neil Osterweil
Publish date: May 31, 2015
Key clinical point: The investigational monoclonal antibody daratumumab was effective in patients with heavily pretreated multiple myeloma.
News
- Author:
- Neil Osterweil
Publish date: May 30, 2015
Key clinical point: Adding obinutuzumab to bendamustine extended progression-free survival in patients with rituximab-refractory indolent non-Hodgk...
